New data from ADA 2026 reveal that assumptions around age, weight, and gestational history are leaving too many T1D patients misclassified — and the clinical consequences are preventable.
Jessica Dunne
Advertisement
Jessica Dunne, US Medical, Autoimmune Diabetes Medical Director at Sanofi.
Articles by Jessica Dunne
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
3
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
4
Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy
5